Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling

UNSTRUCTURED Advanced cutaneous melanoma has always been a dreaded diagnosis, but with the introduction of a number of practice-changing agents, namely targeted therapy and immunotherapy, considerable strides have been achieved in terms of survival rates. However, the introduction of these agents was associated with a variety of dermatological adverse event, some of which have shown a detrimental effect on the continuity of treatment. This holds especially true in the light of the current fragmentation of care provided by the managing health care professionals. This article sheds light on the impact of the scarcity of dermatology specialist input in the management of dermatological adverse events associated with advanced melanoma treatment. Furthermore, it looks into the potential avenues where dermatological input can bridge the gap in the care provided by oncologists, hence standardising the care provided to melanoma patients with dermatological adverse events.

Download Full-text

First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand? (Preprint)

10.2196/preprints.29912 ◽

2021 ◽

Author(s):

Louay Samir Abdulkarim

Keyword(s):

Targeted Therapy ◽

Cutaneous Melanoma ◽

Specific Immunotherapy ◽

Survival Rates ◽

Mek Inhibitor ◽

Advanced Melanoma ◽

First Line ◽

Growth And Survival ◽

Clear Cut ◽

Melanoma Treatment

UNSTRUCTURED Cutaneous melanoma has always been a dreaded diagnosis due to its high mortality rate and its proclivity for invasiveness and metastasis. Historically, advanced melanoma treatment was limited to chemotherapy and nonspecific immunotherapy agents that displayed poor curative potential and high toxicity. However, during the last decade, the evolving understanding of the mutational burden of melanoma and the immune system evasion mechanisms has led to the development of targeted therapy and specific immunotherapy agents that have transformed the landscape of advanced melanoma treatment. Targeted therapy comprises of agents that directly inhibit mutated kinases, namely BRAF and MEK, which have been implicated in the growth and survival of cancerous melanocytes. However, the efficacy of BRAF and MEK inhibitor monotherapies was limited by early resistance and an upsurge in treatment-associated skin tumours. Consequently, a combined BRAF/MEK inhibitor approach was trialled, which resulted in superior survival rates while minimising the aforementioned limitations. On the other hand, specific immunotherapy agents were developed on the heels of Nobel Prize-winning discoveries that outlined the pivotal role of certain immune downregulatory signals that facilitate tumour growth. Despite the considerable strides in understanding the clinical implication of these agents, there is a scarcity in randomised clinical trials that directly compare the efficacy of the aforementioned agents, hence there are no clear-cut preferences among the available first-line options. This paper attempts to summarise the current understanding of first-line treatments. Additionally, it describes the indirect comparative evidence that aids in bridging the gap in the literature.

Download Full-text

Perspective approach for cutaneous melanoma treatment by cationic peptides

Journal of Cancer Prevention & Current Research ◽

10.15406/jcpcr.2020.11.00442 ◽

2020 ◽

Vol 11 (6) ◽

pp. 139-142

Author(s):

Anna A Lushnikova ◽

Galina B Smirnova ◽

Aleksandr V Kostarev ◽

Anastasia V Onyan ◽

Anna A Rudakova ◽

...

Keyword(s):

Cutaneous Melanoma ◽

Cationic Peptides ◽

Melanoma Treatment

Download Full-text

Informal Care and Productivity Losses are Important in Advanced Cutaneous Melanoma: Results of the Dutch Melanoma Treatment Registry

Value in Health ◽

10.1016/j.jval.2016.09.2282 ◽

2016 ◽

Vol 19 (7) ◽

pp. A745-A746

Author(s):

M Franken ◽

B Leeneman ◽

A Jochems ◽

M Schouwenburg ◽

M Aarts ◽

...

Keyword(s):

Informal Care ◽

Cutaneous Melanoma ◽

Productivity Losses ◽

Melanoma Treatment

Download Full-text

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Cancers ◽

10.3390/cancers12041003 ◽

2020 ◽

Vol 12 (4) ◽

pp. 1003

Author(s):

Brenda Leeneman ◽

Carin A. Uyl-de Groot ◽

Maureen J. B. Aarts ◽

Alexander C. J. van Akkooi ◽

Franchette W. P. J. van den Berkmortel ◽

...

Keyword(s):

Metastatic Melanoma ◽

Real World ◽

Systemic Therapy ◽

Cutaneous Melanoma ◽

Healthcare Costs ◽

New Drugs ◽

Targeted Drugs ◽

Melanoma Treatment ◽

Line Of Therapy ◽

Insight Into

Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all patients, patients who did not receive systemic therapy, and patients who received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€ 6809: € 7988/€ 2483 for patients who did not receive systemic therapy (n = 784) and € 105,078/€ 7652 for patients who received systemic therapy (n = 4022). Mean episode/monthly costs were the highest for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh their costs.

Download Full-text

Differences in cutaneous melanoma treatment and patient satisfaction

PLoS ONE ◽

10.1371/journal.pone.0205517 ◽

2018 ◽

Vol 13 (10) ◽

pp. e0205517 ◽

Cited By ~ 3

Author(s):

Jakob D. Wikstrom ◽

Lena Lundeberg ◽

Margareta Frohm-Nilsson ◽

Ada Girnita

Keyword(s):

Patient Satisfaction ◽

Cutaneous Melanoma ◽

Melanoma Treatment

Download Full-text

Thrombospondin-1 and Cutaneous Melanoma

Journal of Cutaneous Medicine and Surgery ◽

10.1177/120347540300700208 ◽

2003 ◽

Vol 7 (2) ◽

pp. 136-141 ◽

Cited By ~ 3

Author(s):

M. J. Trotter ◽

R. Colwell ◽

V. A. Tron

Keyword(s):

Tumor Progression ◽

Cutaneous Melanoma ◽

Malignant Tumors ◽

Antiangiogenic Effect ◽

Poor Prognostic Factor ◽

Cell Functions ◽

Thrombospondin 1 ◽

Associated Proteins ◽

Melanoma Treatment

Background: Thrombospondins (TSPs) are recognized as important glycoproteins that regulate a wide variety of cell functions and interactions. TSPs in malignant tumors can both enhance and inhibit tumor progression, invasion, and metastasis, depending on cell type, stromal interactions, and microenvironment. These proteins are potential targets for anticancer therapy. Objective: The aim of our article is to review the role of thrombospondin-1 (TSP1) in cutaneous melanoma. Conclusions: TSP1 expression is variable in melanoma cell lines and tumors. Similar to findings in other human cancers, expression of TSP1 by melanoma cells usually inhibits tumor progression via the antiangiogenic effect of TSP1. Conversely, stromal TSP1 overexpression in melanoma is a poor prognostic factor associated with decreased survival. Understanding the interactions of TSP1 with other melanoma- and matrix-associated proteins should provide new prognostic indices and possible therapeutic targets for melanoma treatment.

Download Full-text